A Matching-Adjusted Indirect Comparison (MAIC) of Daratumumab-Bortezomib-Thalidomide-Dexamethasone (D-VTd) Versus Bortezomib-Lenalidomide-Dexamethasone (VRd) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible
暂无分享,去创建一个
P. Sonneveld | P. Moreau | X. Leleu | T. Facon | M. Attal | C. Hulin | A. Lam | S. Côté | T. Kampfenkel | Yannan Hu | Carla de Boer | M. Hashim